Literature DB >> 25456764

Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.

Gilles Lambert, Mathias Chatelais, Francine Petrides, Maxime Passard, Aurélie Thedrez, Kerry-Anne Rye, Uwe Schwahn, Viktoria Gusarova, Dirk J Blom, William Sasiela, A David Marais.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25456764     DOI： 10.1016/j.jacc.2014.07.995

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  13 in total

1.  Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Authors:  Hagai Tavori; Ilaria Giunzioni; Irene M Predazzi; Deanna Plubell; Anna Shivinsky; Joshua Miles; Rachel M Devay; Hong Liang; Shirya Rashid; MacRae F Linton; Sergio Fazio
Journal:  Cardiovasc Res       Date:  2016-03-15       Impact factor: 10.787

2.  Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.

Authors:  Aurélie Thedrez; Dirk J Blom; Stéphane Ramin-Mangata; Valentin Blanchard; Mikaël Croyal; Kévin Chemello; Brice Nativel; Matthieu Pichelin; Bertrand Cariou; Steeve Bourane; Lihua Tang; Michel Farnier; Frederick J Raal; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-12-28       Impact factor: 8.311

Review 3.  Novel Therapies for Familial Hypercholesterolemia.

Authors:  Justin Parizo; Ashish Sarraju; Joshua W Knowles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

4.  A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes.

Authors:  Anke Loregger; Emma Claire Laura Cook; Jessica Kristin Nelson; Martina Moeton; Laura Jane Sharpe; Susanna Engberg; Madina Karimova; Gilles Lambert; Andrew John Brown; Noam Zelcer
Journal:  Mol Cell Biol       Date:  2015-11-02       Impact factor: 4.272

5.  Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Gary Bradwin; Lynda Rose
Journal:  Eur Heart J       Date:  2015-10-27       Impact factor: 29.983

Review 6.  PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.

Authors:  M John Chapman; Jane K Stock; Henry N Ginsberg
Journal:  Curr Opin Lipidol       Date:  2015-12       Impact factor: 4.776

Review 7.  Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.

Authors:  Matthew K Ito; Gerald F Watts
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

Review 8.  Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.

Authors:  Alberico Luigi Catapano; Angela Pirillo; Giuseppe Danilo Norata
Journal:  Vasc Health Risk Manag       Date:  2017-09-04

9.  Case Studies in Pediatric Lipid Disorders and Their Management.

Authors:  Ambika P Ashraf; Bhuvana Sunil; Vaneeta Bamba; Emily Breidbart; Preneet Cheema Brar; Stephanie Chung; Anshu Gupta; Aditi Khokhar; Seema Kumar; Marissa Lightbourne; Manmohan K Kamboj; Ryan S Miller; Nivedita Patni; Vandana Raman; Amy S Shah; Don P Wilson; Brenda Kohn
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

Review 10.  New developments in atherosclerosis: clinical potential of PCSK9 inhibition.

Authors:  Ilaria Giunzioni; Hagai Tavori
Journal:  Vasc Health Risk Manag       Date:  2015-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.